Adicet Bio Reports Positive Phase 1 Data for Prula-cel in Lupus: 50% CRR, 54% DORIS Remission
ACET sits 49% above its 52-week low of $6.01 on elevated volume (5.4× avg).
Summary
Adicet Bio announced positive Phase 1 data for prula-cel in lupus, showing 50% complete renal response and 54% DORIS remission at 12 months with a favorable safety profile. The company has aligned with the FDA on a pivotal study design and plans to initiate start-up activities in Q4 2026.
Key Events · Product Development and Regulatory · ACET
-
Phase 1 Efficacy Data
Prula-cel achieved 50% 12-month complete renal response (CRR) in lupus nephritis patients and 54% 12-month DORIS remission across 22 efficacy-evaluable patients with 6-21 months follow-up.
-
Favorable Safety Profile
Across 24 safety-evaluable patients, no CRS greater than Grade 2, no IEC-HS, no ICANS, and no dose-limiting toxicities. Grade 1-2 CRS occurred in 25% of patients.
-
FDA Pivotal Study Alignment
Company aligned with FDA on a single-arm pivotal study in lupus nephritis with complete renal response at 12 months as primary endpoint. Start-up activities planned for Q4 2026.
-
Immune Reset Biomarkers
100% (22/22) of efficacy-evaluable patients achieved undetectable CD19+ B cells followed by naïve-dominant B-cell reconstitution. 91% showed anti-dsDNA reduction and 90% showed complement recovery.
Analysis · ACET · Life Sciences
Prula-cel delivered compelling Phase 1 data in heavily pre-treated lupus patients, with 50% complete renal response in lupus nephritis and 54% DORIS remission at 12 months. The safety profile is notably clean for a CAR-T therapy — no CRS above Grade 2, no ICANS, no IEC-HS — supporting outpatient administration. Critically, the company has aligned with the FDA on a single-arm pivotal study design in lupus nephritis, with start-up activities planned for Q4 2026. This transforms prula-cel from an early-stage asset into a registrational-ready program with a clear path to approval. For a company with a market cap under $85 million, positive pivotal-enabling data in a large autoimmune indication represents a thesis-altering event.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACET was trading at $8.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.4M. The 52-week trading range was $6.01 to $17.44. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.